Hysteroscopy and hysteroscopic electrosurgery of endometrial polyps are currently the preferred methods of diagnosis and treatment of endometrial polyps, which have a high recurrence rate after surgery. The main reason for this analysis is that women with long-term progestin-free counteracting or high estrogen levels are prone to endometrial polyps, and surgical excision only achieves the symptomatic effect of the disease. Therefore, postoperative administration of progestin to counteract estrogen and promote the transformation of the endometrium to the secretory phase is an effective way to prevent polyps. Progestins are available in various dosage forms, including oral preparations, intrauterine extended-release agents, and subcutaneous implants, etc. They are one of the most important hormones regulating the female reproductive system. Periodic oral progestins can inhibit endometrial hyperplasia and promote endometrial transformation, and are a common method to prevent recurrence in patients with endometrial polyps with high-risk factors. The commonly used method is supplementation with natural progestins such as dydrogesterone or progesterone capsules during the second half of menstruation, which can supplement the luteal function while preventing polyps, and can achieve pregnancy support and early pregnancy preservation in women with concomitant infertility. For women without fertility requirements, short-acting oral contraceptive drug cycles can be chosen. The linked application of estrogen and progestin in oral contraceptives, estrogen promotes the repair of endometrium after polypectomy, and progestin can inhibit endometrial proliferation and play a role in preventing the recurrence of polyps. The new generation of oral contraceptives, which are widely used nowadays, have no adverse effects on coagulation function and lipid metabolism, and can reduce water and sodium retention and have the effect of weight control. The most important thing is that pregnancy can be achieved in the next month after stopping the pill, and there is no adverse effect on pregnancy. LNG-IUS provides a new route of progestin administration with easy-to-use, localized drug release. LNG-IUS releases 20 μg of levonorgestrel daily in the uterine cavity, which acts on the endometrium, causing it to atrophy and become inactive and increasing the viscosity of cervical mucus. endometrium-related pathologies such as menorrhagia. This topical extended-release progestin is easy to use and has a high concentration in the target organ, the endometrium, and a very low blood concentration, with a concentration ratio of nearly 8,000, which achieves good inhibition of endometrial hyperplasia while minimizing drug-induced adverse effects.